HomeTrialNCT03955445
🔬NCT03955445Phase 3RECRUITING

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Study Summary

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment225 participants
Primary Completion
Lead SponsorNovartis Pharmaceuticals
Data Retrieved2026-04-11 02:55:49.151450+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.